SCHEMBL15344985

SCHEMBL15344985

Cc1ccnc(-c2ccc3nn(C)cc3c2C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
BRD4 O60885 1/20 0.41
CREBBP Q92793 1/20 0.41
LRRK2 Q5S007 2/20 0.37
TGFBR1 P36897 1/20 0.37
JMJD6 Q6NYC1 4/20 0.36
CYP2A6 P11509 1/20 0.36
METAP2 P50579 1/20 0.36
UHRF1 Q96T88 1/20 0.34
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
KMT2A Q03164 1/20 0.33
PRKD1 Q15139 1/20 0.32
ADRA1D P25100 2/20 0.32
ADRA1A P35348 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15341919 0.85 BRD4 (0.38) CCR1CCR5CCR8BRD4CREBBP
SCHEMBL13218686 0.74 CCR1 (0.55) CCR1CCR5CCR8BRD4LRRK2
SCHEMBL15344953 0.73 CCR1 (0.46) CCR1CCR5CCR8BRD4CREBBP
SCHEMBL15344989 0.73 CCR1 (0.53) CCR1CCR5CCR8LRRK2TGFBR1
SCHEMBL31219993 0.71 PTPN11 (0.34) BRD4CREBBP
SCHEMBL15344997 0.71 CCR1 (0.46) CCR1CCR5CCR8BRD4CREBBP
SCHEMBL19538835 0.70 PDE3B (0.40) CCR1CCR5CCR8BRD4CREBBP
SCHEMBL15344983 0.70 CCR1 (0.53) CCR1CCR5CCR8LRRK2TGFBR1
SCHEMBL28927800 0.69 CCR1 (0.47) CCR1CCR5CCR8LRRK2TGFBR1
SCHEMBL17876889 0.69 CYP2A6 (0.39) CCR1CCR5CCR8BRD4CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CCR1 106/4885CCR5 3/4885CCR8 125/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CCR1 106/4885CCR5 3/4885CCR8 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.